Highly Efficient Gene Expression in Rabbit Synoviocytes Using EBV-Based Plasmid.
- Author:
Jin Young KIM
1
;
Sang Taek OH
;
Jeehee YOUN
;
Suk Kyeong LEE
Author Information
- Publication Type:Original Article
- Keywords: Rheumatoid arthritis; EBV-based plasmid; IL-10; vIL-10; synoviocyte; rabbit
- MeSH: Arthritis, Rheumatoid; Clone Cells; Cloning, Organism; Cytokines; Enzyme-Linked Immunosorbent Assay; Gene Expression*; Genetic Therapy; Inflammation; Interleukin-10; Joints; Microscopy, Confocal; Plasmids*; Transfection
- From:Immune Network 2004;4(3):190-197
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic synovial inflammation which leads to joint destruction. Gene therapy of RA targets the players of inflammation or articular destruction. However, viral vectors have safety problems and side effects, while non-viral vectors suffer from inefficient gene transfer and fast loss of gene expression. To overcome the limits of non-vial vectors, an EBV-based plasmid which is known to exert prolonged high level gene expression can be used. METHODS: pEBVGFP, pEBVIL-10, and pEBVvIL-10 were constructed by cloning GFP, IL-10, and vIL-10 genes into an EBV-based plasmid, respectively. The pGFP was used as a control plasmid. Each constructs were lipofected into HIG-82 rabbit synoviocytes. The expression of GFP was monitored by FACS and confocal microscopy. IL-10 and vIL-10 expressions were measured by ELISA. RESULTS: GFP expression 2 days after transfection was achieved in 33.2% of cells. GFP-expressing cells transfected with pGFP decreased rapidly from 4 days after transfection and disappeared completely by 11 days. Cells transfected with pEBVGFP began to decrease slowly from 4 days. But GFP expression was detected for over 35 days. In addition, HIG-82 cells transfected with pEBVIL-10 (44.6+/-1.5 ng/ml) or pEBVvIL-10 (51.0+/-5.7 ng/ml) secreted these cytokines at high levels. High level cytokine production by hygromycin selection was maintained at least for up to 26 days after transfection. CONCLUSION: These results suggest that the EBV-based plasmid has a potential to improve non-viral gene transfer system and may be applicable to treat RA without the drawbacks of viral vectors.
